aTyr Pharma, Inc.
9 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) (NCT05892614) | aTyr Pharma, Inc. | 2023-10-26 |
| Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis (NCT05415137) | aTyr Pharma, Inc. | 2022-09-15 |
| Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19 (NCT04412668) | aTyr Pharma, Inc. | 2020-06-04 |
| Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis (NCT03824392) | aTyr Pharma, Inc. | 2019-01-29 |
Track aTyr Pharma, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.